Psoriasis is a chronic, immune-mediated, inflammatory, and debilitating skin disease with significant impact on patients' quality of life. Its pathogenesis is complex and not yet fully understood. However, the IL-23/IL-17 axis is currently considered the main pathogenic pathway in psoriasis. Guselkumab is a fully human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that binds to the p19 subunit of IL-23. It is the first of its class, already approved by the US Food and Drug Administration (FDA), as well as the European Medicines Agency (EMA) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for either systemic therapy or phototherapy. Several clinical trials have demonstrated potential benefits of guselkumab over other already approved immunomodulators in terms of safety and efficacy. The results of the head-to-head trial ECLIPSE were recently released and are addressed in this review. They contribute to the increasing confidence in guselkumab, demonstrating great potential for long-term treatment of psoriasis. However, further long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis.
Introduction
Psoriasis is a chronic, immune-mediated, inflammatory skin disease that affects over 125 million people worldwide, [1] [2] [3] with significant impact on patients' quality of life. 4 Due to its systemic nature, psoriasis is associated with several medical comorbidities, including cardiovascular disease, inflammatory bowel disease, and psychiatric diseases. [5] [6] [7] [8] [9] Psoriasis pathogenesis is complex and not yet fully understood. Even though, disease knowledge has significantly evolved in past years leading to the development of increasingly specific and efficacious targeted therapies. [10] [11] [12] [13] During the initiation phase of the psoriatic skin lesions, an increment of the production of TNF occurs and, as a result, activation of dermal dendritic cells. 14, 15 These cells are responsible for the increased production of IL-23 and the subsequent activation of distinct subgroups of IL-17 producing cells (T17) (helper T cells [Th17] ; cytotoxic T cells [Tc17] ; innate lymphoid cells [ILC3] ; and γδ T cells). 14, [16] [17] [18] As IL-23 levels rise, secreted mainly from inflammatory dermal dendritic cells, T17 cells increase in number and produce large amounts of IL-17, specifically isoforms IL-17A and F, which drive the upregulation of many psoriasis-related genes. 14, 19 The clonal expansion of T17 cells and subsequent increased levels of IL-17 feedforward an inflammatory response and lead to keratinocyte hyperproliferation. 14, 15, 20, 21 Other types of cells, such as dermal macrophages and epidermal keratinocytes, were also associated with the increased production of IL-23 and may contribute to psoriatic lesions' installation and maintenance. 14, 22 The discovery of the IL-23/IL-17 axis, widely considered the most critical pathogenic pathway on the development of psoriasis, and the development of drugs targeting this pathway shifted the paradigm of the management of this condition. 15, 20, 23 The development of IL-17 inhibitors showed that the blockade of the pathway of this cytokine was associated with high levels of efficacy and rapid onset of action in moderate-to-severe psoriasis, but also better clinical responses than either TNF-α inhibitors or ustekinumab, a nonselective IL-23 inhibitor. [24] [25] [26] [27] [28] [29] [30] [31] However, several side effects such as neutropenia, candidiasis, and exacerbations of Crohn's disease have been associated with these agents, [24] [25] [26] [27] [28] [29] [30] [31] reinforcing the need for new therapeutic solutions. More recently, selective IL-23 inhibitors such as guselkumab, tildrakizumab, and risankizumab have emerged, showing a very effective, durable, and safe profile [32] [33] [34] [35] [36] [37] [38] [39] [40] ISSN: 1740-4398 REVIEW -Guselkumab for the treatment of psoriasis drugsincontext.com This article intends to review the current literature on guselkumab in the management of psoriasis.
Guselkumab pharmacology
Guselkumab® (Janssen Biotech, Inc., Horsham, PA, USA) is a fully human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that binds to the p19 subunit of IL-23. It is first of its class to be approved by the US Food and Drug Administration (FDA) 41 as well as the European Medicines Agency (EMA) 42, 43 for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for either systemic therapy or phototherapy. In light of its clinical efficacy in plaque psoriasis, guselkumab has also been or is currently being evaluated for the treatment of other diseases, namely generalized pustular psoriasis (GPP), erythrodermic psoriasis (EP), psoriatic arthritis, rheumatoid arthritis, and Crohn's disease.
Pharmacodynamic properties
Guselkumab binds with both high affinity and high specificity to IL-23, 43 preventing the interaction of the cytokine with its receptor on the surface of the cell. This action is responsible for blocking the initiation of the IL-23 pathway and the subsequent release of other proinflammatory cytokines ( Figure 1 ).
In patients with moderate-to-severe plaque psoriasis, the biopsy of skin samples from body regions affected with the disease, compared to nonlesional regions, before and after a single dose of guselkumab, showed that the drug is responsible for a significant (p<0.05) reduction in inflammatory dendritic cell and T-cell counts, and epidermal thickness at week 12 compared to baseline. 32 Significant reductions in IL-17A serum levels since week 1 were observed when compared to baseline values (versus no change in placebo recipients) in patients considered as responders to guselkumab (with ≥50% improvement in the Psoriasis Area and Severity Index score [PASI 50] measured at week 12), with a response that was dose-dependent. 32 Guselkumab has also shown a substantial impact in both the reduction of mRNA expression of IL-17F and IL-22, as well as in increased levels of INF-γ, produced by T-helper 1 (Th1) cells, thus proposing that the drug's clinical performance relies primarily in the inhibition of the IL-23/Th17 pathway, allowing the IL-12/Th1 axis to remain intact 32 ( Figure 1 ).
Pharmacokinetic properties
Zhuang and colleagues 37 conducted a first-in-human, phase I, randomized trial to assess the pharmacokinetics, immunogenicity, safety, and tolerability of guselkumab following a single intravenous (IV; 0.03-10 mg/kg) or subcutaneous (SC; 10-300 mg) administration in healthy subjects and patients with moderate-to-severe psoriasis. The pharmacokinetic profile of guselkumab was generally comparable between healthy subjects and patients with psoriasis. Investigators also noted that there was a 
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Regional psoriasis was also evaluated and analysed in this trial. For this purpose, investigators used scores such as scalpspecific IGA (ss-IGA), Nail Psoriasis Severity Index (NAPSI), fingernail Physician's Global Assessment (PGA) (f-PGA), and PGA of the hands and/or feet (hf-PGA). A significantly greater proportion of patients treated with guselkumab reached an ss-IGA score of 0/1 compared with placebo at week 16 (83.4 versus 14.5%; p<0.001). Using the same score, guselkumab also showed significantly higher efficacy than adalimumab at weeks 24 (84.5% in guselkumab group versus 69.2% in adalimumab group) and 48 (78.3% in guselkumab group versus 60.5% in adalimumab group) (both p<0.001). 34 Compared to placebo at week 16, the guselkumab group had a higher mean per cent improvement in the NAPSI score and a greater proportion of patients achieving an f-PGA score of 0/1. Compared to adalimumab, the results in the f-PGA score were similar at week 24 but significant differences were observed at week 48 in patients treated with guselkumab (p=0.038). 34 There were no differences between guselkumab and adalimumab groups concerning the NAPSI score, measured at weeks 24 and 48. 34 dose-dependent increase in the mean maximum serum concentration and area under the zero-to-infinity serum concentration-time curve. 37 Yao and colleagues 44 established a population pharmacokinetics model using the information from three clinical trials involving guselkumab: the phase II X-PLORE (NCT01483599) and two phase III trials, namely VOYAGE 1 (NCT02207231) and VOYAGE 2 (NCT02207244). The final model showed an apparent clearance and apparent volume of distribution of 0.516 L/day, and 13.5 L, respectively. Mean half-life time values were consistent between both healthy subjects (12-19 days) and patients with psoriasis (15-17 days).
The model-derived elimination half-life of the drug allowed for the conclusion that steady-state serum guselkumab concentrations occurred between weeks 12 and 14. 44 However, Smolen and colleagues 45 reported that the median serum levels of guselkumab would only reach the steady state by week 20, which is the information provided by EMA about the product. 43 
Therapeutic efficacy of guselkumab in psoriasis
Large, randomized, multinational, phase III trials (VOYAGE 1, VOYAGE 2, NAVIGATE [NCT02203032], and ECLIPSE [NCT03090100]) assessed the clinical efficacy of subcutaneous guselkumab in the treatment of moderate-to-severe plaque psoriasis in adults. Results from other trials support this data and will not be discussed further. 33, 46 Patients enrolled in the previously reported phase III clinical trials were individuals with ≥18 years of agewith moderateto-severe plaque psoriasis for at least 6 months and had to be eligible for systemic therapy or phototherapy. Patients in VOYAGE trials and NAVIGATE had an initial Investigator Global Assessment (IGA) score of 3 or more, a minimum affected body surface area (BSA) of ≥10%, and a PASI score of 12 or more. These studies excluded patients with history or symptoms of active tuberculosis, other types of psoriasis (guttate, erythrodermic, or pustular), or who had been exposed to guselkumab or the active comparator (adalimumab in VOYAGE trials; ustekinumab in NAVIGATE; and secukinumab in ECLIPSE). [34] [35] [36] 38 VOYAGE trials VOYAGE 1 was a phase III randomized, double-blind trial, which evaluated the effectiveness of guselkumab compared to placebo and adalimumab. 34 For study design, see Table 1 . The proportion of patients with an IGA score of 0/1 (cleared/ minimal disease) and the proportion of patients with an at least PASI 90 response, both at week 16, were used to evaluate the clinical efficacy of guselkumab compared to placebo (as coprimary endpoints). To assess the efficacy of guselkumab compared to that of adalimumab, investigators used as major secondary endpoints the proportion of patients achieving an
Health-related quality of life (HRQoL) was also evaluated with patient-reported outcomes using the Psoriasis Symptoms and Signs Diary (PSSD) and the Dermatology Life Quality Index (DLQI). Mean changes in the PSSD score from baseline for guselkumab-treated patients were higher than placebo at week 16 and higher than adalimumab at weeks 24 and 48 (p<0.001 for all three). It was possible to observe a significantly higher improvement from baseline DLQI in the group of patients who received guselkumab compared with placebo (−11.2±7. 34 Still in VOYAGE 1, an open-label extension period began where patients who were having guselkumab as treatment agreed to continue to receive the drug every 8 weeks, whereas patients in the adalimumab group accepted to change to guselkumab at week 52 and every 8 weeks thereafter, after taking their last dose of adalimumab at week 47. At week 100, the proportion of patients who achieved an IGA score of 0/1, the IGA score of 0, PASI 75, PASI 90, and PASI 100 responses were 82.4, 53.8, 94.8, 82.1, and 49.0%, respectively. Placebo-guselkumab crossover and adalimumab-guselkumab crossover groups achieved similar results at week 100. It was concluded that efficacy was maintained through 2 years amongst patients who had continued treatment with guselkumab, and patients who changed from adalimumab to guselkumab after 1 year had improved efficacy at 2 years. 47 In VOYAGE 2 trial, investigators assessed the efficacy and safety of guselkumab in moderate-to-severe psoriasis versus both 36 The investigators defined the number of visits in which randomized patients achieved an IGA score of 0/1 and at least a two-grade improvement in the IGA score (comparing to the IGA score at week 16) from week 28 through week 40 as the primary endpoint. 36 The number of visits in which randomized patients achieved IGA of 0/1 was significantly higher in the group of patients receiving guselkumab versus the group receiving ustekinumab (1.5±1.6 versus 0.7±1.3; p≤0.001). 36 Langley and colleagues 36 36 For a more detailed analysis of the results, see Table 2 . This clinical trial gave us the opportunity to conclude that patients treated with ustekinumab who had a poor response at week 16 derived significant benefit from switching to guselkumab. 36 
ECLIPSE
A phase III randomized, double-blind, head-to-head trial called ECLIPSE was designed to assess guselkumab's efficacy and safety compared to secukinumab in patients with moderate-tosevere plaque psoriasis. For study design, consult Table 1 .
The study demonstrated that guselkumab was superior to secukinumab for the primary endpoint assessed at week 48; that is, achievement of at least PASI 90 response (84.5% with guselkumab versus 70.0% with secukinumab; p<0.001). 38 For a more detailed analysis of the results, see 
Safety and tolerability of guselkumab
Guselkumab was generally well tolerated in adults with moderate-to-severe plaque psoriasis in all pivotal trials. [34] [35] [36] 38 Data from other phase I, II, and III trials support this information 32,33,46 and will not be discussed further.
In VOYAGE 1, investigators reported comparable adverse events (AEs) amongst patients in the different treatment groups. Nasopharyngitis and upper respiratory tract infection were the most common adverse events reported. 34 In addition to the fact that serious AEs and AEs leading to the discontinuation of the agent were uncommon, these events occurred in similar proportions for each treatment group throughout the study. Overall infections and infections requiring antibiotic treatment occurred at comparable rates across all treatment groups through week 48. 34 By week 16, two major adverse cardiac events (MACEs) occurred, one in each of the guselkumab and adalimumab groups, and one patient receiving guselkumab developed a basal cell carcinoma. Between weeks 16 and 48, four cases of serious infections were reported: two in the group of patients receiving guselkumab (one thigh abscess and one cellulitis with postoperative wound infection) and two in the group of patients receiving adalimumab (one abdominal abscess and one fatal staphylococcal pneumonia). Two malignancies (breast and prostate cancers), both in the guselkumab group, and two basal cell carcinomas, one in each of the guselkumab and adalimumab groups, were observed up to week 48. No additional MACEs were reported after week 16. There were no differences between groups in the incidence ISSN: 1740-4398 REVIEW -Guselkumab for the treatment of psoriasis drugsincontext.com of neutropenia and candidiasis, which was low in all treatment groups. There were no differences between groups regarding the incidence of laboratory abnormalities, which was also low. No Crohn's disease-related events were reported. 34 VOYAGE 2 corroborated the safety data observed in VOYAGE 1 regarding the comparable proportion of patients with one or more AE, AEs leading to discontinuation, and serious AEs in placebo and guselkumab groups through week 16. 35 The most commonly reported events during placebo-controlled period (weeks 0-16) were nasopharyngitis, headache, and upper respiratory tract infection. That was the same pattern of AEs that were observed during the active-comparator period (weeks 0-28). No malignancies or nonmelanoma skin cancers (NMSCs) were reported through week 16. One MACE, specifically a myocardial infarction, occurred in the group of patients receiving the active-comparator adalimumab during placebocontrolled period. A higher proportion of patients treated with adalimumab had Injection site reactions (ISR) (6.9 versus 2.6%). 35 Concerning to the active-comparator period, three serious infections were observed in each of the active treatment groups (guselkumab group: bronchitis, erysipelas, and soft tissue infection; adalimumab group: two cases of tuberculosis and one injection-site abscess). One malignancy (prostate cancer) and two NMSCs (one squamous cell carcinoma in the group of patients receiving guselkumab and one basal cell carcinoma in the placebo-guselkumab crossover group) were also reported. One patient in each of guselkumab-and adalimumab-treated groups developed a MACE through week 28. 35 From weeks 28 to 48, one serious infection was reported in the maintenance group (appendicitis). During this randomized withdrawal and retreatment period (weeks 28-48), one case of MACE was reported in the placebo-guselkumab crossover group. One additional basal cell carcinoma and one squamous cell carcinoma were noted in the same placebo-guselkumab group through week 48. Similar to what was observed in VOYAGE 1 results, the incidence of laboratory abnormalities was low and comparable between groups. 35 No new signs that would endanger the safety of the drug were identified during the long-term treatment (through 100 weeks) with open-label extension with guselkumab in VOYAGE 1 and VOYAGE 2. 49 NAVIGATE brought no new safety data regarding patients who switched from ustekinumab to guselkumab without a washout period. Moreover, 64.0% of patients randomized to guselkumab had one or more AEs (versus 56.0% in ustekinumab group). Serious AEs were reported in 7% of patients treated with guselkumab (versus 5% with ustekinumab), and 2% of each group discontinued treatment due to an AE. 36 In the ECLIPSE trial, the safety profiles observed for both drugs (guselkumab and secukinumab) were consistent with the information already presented in the respective registration trials. Similar percentage of patients reported at least one AE (77.9% with guselkumab versus 81.6% with secukinumab). Serious AEs were reported in 6.2% of patients receiving guselkumab (versus 7.2% of patients receiving secukinumab). Investigators documented six serious infections in guselkumabtreated patients (versus five in the secukinumab group). 38 
Immunogenicity
Zhuang and colleagues 37 reported that 1 out of 20 (5.0%) patients in the second part of the phase I trial (which included patients with psoriasis) had positive antibodies to guselkumab. The incidence of antibodies to guselkumab reported in X-PLORE was 6.0%. 33 However, they were nonneutralizing and had low titres. 33 VOYAGE 1, VOYAGE 2, and NAVIGATE reported rates of antibody development of 5.3% through week 44, 6 .6% through week 48, and 9.0% through week 60, respectively. No association between antibody incidence and reduced efficacy was noted. [34] [35] [36] Other indications
A phase III, single-arm, open-label, multicentre trial conducted in Japan with 21 patients demonstrated the clinical benefit of using guselkumab in the treatment of other types of psoriasis, such as GPP and EP. 50 Its efficacy was verified throughout the study period (52 weeks), and the safety profile of guselkumab was consistent with data already published in psoriasis. Sano and colleagues 50 concluded that there would be a favourable risk-benefit profile for treating both GPP and EP patients with the selective IL-23 inhibitor. Nevertheless, further studies are required to confirm this effectiveness.
In a phase II randomized, double-blind, placebo-controlled trial, guselkumab demonstrated significant improvement in joints' symptoms, physical function, enthesitis, dactylitis, and quality of life in patients with psoriatic arthritis. 51 Two phase III trials are now underway to ascertain the efficacy and safety of guselkumab in patients who suffer from this pathological condition, either biologic-naive (NCT03158285) or previously treated with TNF-α inhibitors (NCT03162796).
Smolen and colleagues 45 conducted a phase II trial that evaluated the safety and efficacy of guselkumab in patients suffering from active rheumatoid arthritis despite concomitant treatment with methotrexate. No statistically significant differences in the percentage of patients who achieved an American College of Rheumatology (ACR)-20 response between those who received guselkumab and the control group were found. 45 To date, no published studies demonstrate the impact of guselkumab in the treatment of Crohn's disease. However, ustekinumab, as a nonselective IL-23 inhibitor, has been shown to be effective treating this disease. 52, 53 Currently, a clinical trial is ongoing (GALAXI [NCT03466411]), and is recruiting patients and pretends to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
Discussion
As previously mentioned, the discovery of the IL-23/IL-17 axis has led to a substantial increase in our knowledge of the ISSN: 1740-4398 REVIEW -Guselkumab for the treatment of psoriasis drugsincontext.com pathogenic immune events present in psoriasis and to shift the paradigm of the management of this condition. IL-17 inhibitors were approved previously than IL-23 selective inhibitors for the treatment of moderate-to-severe psoriasis. However, several complications have been associated with these agents, raising the need for different therapeutic solutions.
Although the inhibition of IL-23 alone rather the coinhibition of both IL-23 and IL-12 presents as a novel mechanism of action, the favourable safety profile of guselkumab has not come as a surprise, because long-term data were available for ustekinumab. 53, 54 However, allowing the IL-12/Th1 axis to remain intact, as is the case with guselkumab, may be a net-positive effect because the cytokines involved in this pathway contribute vitally to the hosts' defence through their ability to stimulate both innate and adaptive immune effector cells against intracellular microbial infection and malignant cells. [55] [56] [57] These cytokines also allow the initiation of a protective transcriptional program in keratinocytes that will limit skin inflammation mediated by T17 cells. 15, 58 Treatment with an IL-23p19 inhibitor led to long-term responses in some patients with just a single dose 32 or after a withdrawal after 28 weeks of contact with the drug (in VOYAGE 2, 36.8% of patients rerandomized to placebo sustained PASI 90 at week 48). 35 This clinical response can be explained in part by the impact of IL-12 in promoting transdifferentiation of Th17 cells into regulatory T cell or Th1 populations. 15, 59 Although IL-23 and IL-39 (another proinflammatory cytokine likely expressed in psoriatic skin) share the p19 subunit, whether guselkumab can bind to or inhibit human IL-39 is unknown, and further studies are required to explore the individual role of this cytokine. 20 Several reviews have been published regarding the role of guselkumab in the treatment of psoriasis. [60] [61] [62] [63] However, recent divulgation of the results of ECLIPSE reinforces the role of the selective IL-23 inhibitor concerning other already approved immunomodulators, such as the active-comparator secukinumab used in trial. 38 Even though secukinumab achieved a slightly faster onset of response, detailed analysis with the response-over-time curves showed that maximum response rates with guselkumab are achieved later -after 6 months -and are maintained over time through 1 year, translating into superiority for the primary endpoint of the study (PASI 90 response). 38 The superiority of guselkumab in comparison to secukinumab is also apparent in the less frequent dosing regimen of the selective IL-23 inhibitor (guselkumab: initially at weeks 0 and 4, but then every 8 weeks versus secukinumab: administered weekly for 4 weeks followed by every 4 weeks as a maintenance dosing). From the patients' point of view, characteristics such as less frequent drug administration or the option of self-administration contribute to better adherence and thus better clinical outcomes.
Conclusion
Guselkumab is a monoclonal antibody that selectively targets IL-23, and it is the first in its class to be approved to treat moderate-to-severe plaque psoriasis. Its efficacy and safety profiles were reinforced by recent studies such as ECLIPSE, demonstrating great potential for long-term treatment of psoriasis. Long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis.
